Buckingham Asset Management LLC Has $1.74 Million Stake in Becton, Dickinson and Company (BDX)

Buckingham Asset Management LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 12.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,885 shares of the medical instruments supplier’s stock after selling 1,251 shares during the period. Buckingham Asset Management LLC’s holdings in Becton, Dickinson and were worth $1,741,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares during the last quarter. State Street Corp raised its holdings in shares of Becton, Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Becton, Dickinson and by 4.0% in the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after purchasing an additional 106,966 shares during the last quarter. Finally, Fiera Capital Corp raised its holdings in shares of Becton, Dickinson and by 7.1% in the second quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock valued at $542,825,000 after purchasing an additional 183,372 shares during the last quarter. Institutional investors own 86.01% of the company’s stock.

In other Becton, Dickinson and news, insider Stephen Sichak sold 11,787 shares of the stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the transaction, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary M. Cohen sold 15,044 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the transaction, the insider now owns 95,270 shares of the company’s stock, valued at approximately $19,094,966.10. The disclosure for this sale can be found here. Insiders have sold 47,038 shares of company stock valued at $9,480,225 in the last quarter. Company insiders own 1.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Buckingham Asset Management LLC Has $1.74 Million Stake in Becton, Dickinson and Company (BDX)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2017/11/19/buckingham-asset-management-llc-has-1-74-million-stake-in-becton-dickinson-and-company-bdx.html.

Several analysts have recently commented on BDX shares. Wells Fargo & Company reiterated a “positive” rating and issued a $235.00 target price (up previously from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. BidaskClub downgraded shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies restated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and an average price target of $214.79.

Shares of Becton, Dickinson and Company (NYSE BDX) traded down $1.21 during trading hours on Friday, reaching $220.31. 718,967 shares of the company’s stock were exchanged, compared to its average volume of 1,359,118. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. The company has a market capitalization of $50,134.84, a price-to-earnings ratio of 23.21, a PEG ratio of 1.73 and a beta of 1.04. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $225.23.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The company’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter last year, the business earned $2.12 earnings per share. sell-side analysts expect that Becton, Dickinson and Company will post 10.63 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply